Liposomal paclitaxel
Showing 1 - 25 of 3,837
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,
Recruiting
- Head and Neck Squamous Cell Carcinoma
- +2 more
- Pembrolizumab
- +7 more
-
Beijing, Beijing, ChinaBeijing Tongren Hospital
Oct 26, 2023
Kaposi Sarcoma, HIV-1-infection Trial (Pegylated liposomal doxorubicin, Paclitaxel)
Not yet recruiting
- Kaposi Sarcoma
- HIV-1-infection
- Pegylated liposomal doxorubicin
- Paclitaxel
- (no location specified)
Jan 20, 2023
Angiosarcoma Metastatic Trial in Guangzhou (Abraxane combined with liposomal doxorubicin)
Recruiting
- Angiosarcoma Metastatic
- Abraxane combined with liposomal doxorubicin
-
Guangzhou, Guangdong, ChinaXing Zhang
Sep 4, 2022
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Sintilimab, Liposomal Paclitaxel + Cisplatin + S-1)
Active, not recruiting
- Esophageal Squamous Cell Carcinoma
- Sintilimab
- Liposomal Paclitaxel + Cisplatin + S-1
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital with Nanjing Medical University
Jul 16, 2022
Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Tumors Trial in Houston (BP1001-A (Liposomal Grb2 Antisense
Not yet recruiting
- Solid Tumor, Adult
- +5 more
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel
- (no location specified)
Jun 7, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Phoenix,
Recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +4 more
-
Phoenix, Arizona
- +2 more
Jun 27, 2022
Efficacy and Safety Trial in Zhejiang (pegylated liposomal doxorubicin, paclitaxel, Carboplatin)
Active, not recruiting
- Efficacy and Safety
- pegylated liposomal doxorubicin
- +2 more
-
Zhejiang, Hangzhou, ChinaWomen's Hospital School Of Medicine Zhejiang University
Jul 14, 2022
Breast Cancer, HER2-positive Breast Cancer Trial in Xi'an (pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed
Recruiting
- Breast Cancer
- HER2-positive Breast Cancer
- pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage
-
Xi'an, Shaanxi, ChinaXijing Hospital ， Fourth Military Medical University
Apr 23, 2022
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in United States (Fluorouracil, Gemcitabine,
Recruiting
- Metastatic Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8
- Fluorouracil
- +8 more
-
Boise, Idaho
- +42 more
Jun 8, 2022
Low Grade Serous Ovarian Cancer Trial (avutometinib + defactinib, Investigator Choice of Treatment (ICT))
Not yet recruiting
- Low Grade Serous Ovarian Cancer
- avutometinib + defactinib
- Investigator Choice of Treatment (ICT)
- (no location specified)
Oct 2, 2023
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal
Recruiting
- Platinum-Refractory Fallopian Tube Carcinoma
- +11 more
- Copanlisib Hydrochloride
- +4 more
-
Aurora, Colorado
- +2 more
Dec 8, 2022
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer Trial in New
Suspended
- Estrogen Receptor-negative Breast Cancer
- +8 more
- pegylated liposomal doxorubicin hydrochloride
- +6 more
-
New Brunswick, New JerseyRutgers Cancer Institute of New Jersey
Sep 20, 2021
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer Trial in Orlando, Albuquerque
Recruiting
- Platinum-resistant Ovarian Cancer
- +6 more
- olvimulogene nanivacirepvec
- +3 more
-
Orlando, FloridaAdventHealth Cancer Institute
Sep 1, 2022
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Canada, United States (Nemvaleukin
Recruiting
- Platinum-resistant Ovarian Cancer
- +2 more
- Nemvaleukin and Pembrolizumab Combination
- +6 more
-
Ventura, California
- +7 more
Aug 5, 2022
Metastatic Pancreatic Cancer Trial in France, Martinique (Irinotecan Liposomal Injection, 5-FU/LV, Nab-Paclitaxel)
Recruiting
- Metastatic Pancreatic Cancer
- Irinotecan Liposomal Injection
- +3 more
-
Amiens, France
- +35 more
Mar 23, 2022
Ovarian Epithelial Cancer Trial in Leuven (Olaparib, carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin +
Active, not recruiting
- Ovarian Epithelial Cancer
- Olaparib
- carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
-
Leuven, BelgiumUZLeuven
Jan 26, 2021
Recurrent, Platinum-resistant Ovarian Cancer Trial in Milan (Decitabine, Carboplatin, Pegylated Liposomal Doxorubicin)
Recruiting
- Recurrent, Platinum-resistant Ovarian Cancer
- Decitabine
- +4 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Sep 3, 2021
Pancreatic Adenocarcinoma Trial in France, United Kingdom, United States (eryaspase, Gemcitabine plus Abraxane, Irinotecan plus
Platinum-Sensitive Ovarian Cancer in First Relapse Trial in Worldwide (Farletuzumab, Placebo)
Completed
- Platinum-Sensitive Ovarian Cancer in First Relapse
- Farletuzumab
- Placebo
-
Phoenix, Arizona
- +67 more
Aug 9, 2021
Breast Cancer Trial in Beijing (Pegylated Liposomal Doxorubicin, Albumin-bound paclitaxel, Trastuzumab)
Unknown status
- Breast Cancer
- Pegylated Liposomal Doxorubicin
- +2 more
-
Beijing, Beijing, ChinaFei Ma
Jan 20, 2020
Metastatic Breast Cancer Trial in France (AZD2014, AZD4547, AZD5363)
Active, not recruiting
- Metastatic Breast Cancer
- AZD2014
- +18 more
-
Angers, France
- +24 more
Mar 8, 2022